PROF Profound Medical Corp.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1628808 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY65.3%
TTM net income YoY17.4%
TTM EPS YoY295.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin73.9%
Operating margin-145.1%
Net margin-137.5%
FCF margin—
EBITDA margin-143.4%
Returns
ROE-87.0%
ROA-64.7%
ROIC (approx.)-157.1%
Asset turnover0.47x
Leverage & solvency
Liabilities / assets26.9%
Debt / equity0.21x
Current ratio4.54x
Interest coverage-105.79x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $16.10M | $10.68M |
| Cost of revenue | $4.71M | $3.64M |
| Gross profit | $11.39M | $7.04M |
| R&D expense | $20.60M | $16.96M |
| SG&A expense | $32.05M | $23.13M |
| Operating income | -$41.25M | -$33.06M |
| Interest expense | $394,000 | $600,000 |
| Pretax income | -$42.32M | -$27.82M |
| Income tax | $252,000 | -$2,000 |
| Net income | -$42.57M | -$27.82M |
| EBITDA | -$40.88M | -$32.35M |
| EPS (basic) | 1.41 | 1.12 |
| EPS (diluted) | 1.41 | 1.12 |
| Weighted avg. shares (diluted) | 30.23M | 24.77M |
| Balance sheet | ||
| Cash & equivalents | $59.72M | $54.91M |
| Inventory | $8.24M | $5.80M |
| Current assets | $76.09M | $69.06M |
| PP&E, net | $698,000 | $425,000 |
| Intangibles | $138,000 | $261,000 |
| Total assets | $77.47M | $70.23M |
| Current liabilities | $6.08M | $6.57M |
| Short-term debt | — | $1.74M |
| Long-term debt | $4.50M | $4.66M |
| Total debt | $4.50M | $6.40M |
| Total liabilities | $11.04M | $9.81M |
| Shareholders' equity | $66.43M | $60.42M |
| Net debt | -$55.22M | -$48.51M |
| Shares outstanding | 36.29M | 30.04M |
| Cash flow statement | ||
| Operating cash flow | -$38.21M | -$23.45M |
| Capital expenditure | $176,000 | — |
| Free cash flow | -$38.38M | — |
| Investing cash flow | -$242,000 | — |
| Financing cash flow | $41.14M | $54.70M |
| Depreciation & amortization | $373,000 | $707,000 |
| Stock-based compensation | $5.49M | $2.58M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.